American Oriental Bioengineering Inc. to Present at Roth Capital Conference in New York.

HONG KONG -- American Oriental Bioengineering Inc. (AMEX: AOB), a leading Chinese manufacturer and distributor of plant-based pharmaceutical and nutraceutical products, today announced that Lily Li, the company's operations officer and acting CFO, will present at the Roth Capital Partners New York Conference on Sept. 6 at the Westin New York in Times Square Manhattan. Accompanying her will be the VP of finance, Wilfred Chow. The company's presentation is scheduled for 2 p.m. Eastern and will include an interactive question and answer session. Following the presentation, Li and Chow will be available for one-on-one meetings with analysts and investors, interested parties should contact their Roth Capital representative.

During the presentation, Li and Chow will discuss the company's historical financial performance and ongoing initiatives within each key business segment. Li and Chow will also elaborate on the company's PBP and PBN opportunities, new products and discuss additional opportunities within their addressable markets.

Participation or attendance is by invitation only. Clients interested in attending should contact their Roth Capital representatives. Information on the Roth Capital Partners New York Conference can be found at:

http://www.rothconference.com/

Investors can access a webcast of the presentation at:

http://www.wsw.com/webcast/roth8/aob/

About American Oriental Bioengineering

American Oriental Bioengineering Inc. (AOB) uses proprietary processes for producing soybean protein peptide more efficiently than traditional extracting techniques. These techniques are used to manufacture and formulate supplemental and medicinal products. Soybean peptides are used widely in general food, health food products and medicines, among other applications. AOB also produces Cease-Enuresis Soft Gel, the only Chinese FDA-approved first grade, prescription medicine that is specially formulated to help alleviate bed-wetting and incontinence. The company is a leading producer of products in both the nutraceuticals and pharmaceuticals areas in China. For more information, visit http://www.bioaobo.com.

Safe Harbor Statement

This press release includes certain statements that are not descriptions of historical facts, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. These forward-looking statements may include statements about our proposed discussions related to our business or growth strategy, which is subject to change. Such information is based upon expectations of our management that were reasonable when made but may prove to be incorrect. All of such assumptions are inherently subject to uncertainties and contingencies beyond our control and upon assumptions with respect to future business decisions, which are subject to change. For a further description of other risks and uncertainties, see our most recent Annual Report filed with the Securities and Exchange Commission (SEC) on Form 10-K, and our subsequent SEC filings. Copies of filings made with the SEC are available through the SEC's electronic data gathering analysis retrieval system (EDGAR) at www.sec.gov.